FEM
ABBV icon

Fulcrum Equity Management’s AbbVie ABBV Stock Holding History

Fulcrum Equity Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Sell
1,283
-72
-5% -$15.5K 0.24% 99
2026
Q1 		$295K Buy
1,355
+44
+3% +$9.76K 0.28% 89
2025
Q4 		$300K Sell
1,311
-629
-32% -$143K 0.29% 87
2025
Q3 		$449K Sell
1,940
-1,503
-44% -$306K 0.46% 53
2025
Q2 		$639K Buy
3,443
+44
+1% +$8.18K 0.66% 42
2025
Q1 		$712K Sell
3,399
-272
-7% -$52.9K 0.78% 39
2024
Q4 		$652K Sell
3,671
-3,534
-49% -$650K 0.65% 52
2024
Q3 		$1.42M Sell
7,205
-862
-11% -$161K 1.2% 14
2024
Q2 		$1.38M Buy
8,067
+1,295
+19% +$215K 1.24% 13
2024
Q1 		$1.23M Buy
6,772
+1,860
+38% +$321K 1.45% 21
2023
Q4 		$761K Buy
4,912
+124
+3% +$18.1K 0.94% 23
2023
Q3 		$714K Buy
4,788
+1,620
+51% +$238K 0.84% 34
2023
Q2 		$427K Buy
3,168
+45
+1% +$6.6K 0.5% 51
2023
Q1 		$498K Buy
3,123
+1,547
+98% +$237K 0.47% 56
2022
Q4 		$255K Buy
+1,576
New +$242K 0.21% 61
2022
Q1 		– Sell
-2,352
Closed -$318K – 106
2021
Q4 		$318K Sell
2,352
-53
-2% -$6.26K 0.12% 123
2021
Q3 		$259K Buy
2,405
+20
+0.8% +$2.29K 0.1% 147
2021
Q2 		$269K Buy
2,385
+191
+9% +$21.5K 0.1% 157
2021
Q1 		$237K Buy
2,194
+163
+8% +$17.4K 0.09% 158
2020
Q4 		$218K Buy
+2,031
New +$195K 0.09% 149
2020
Q3 		– Sell
-3,991
Closed -$392K – 145
2020
Q2 		$392K Buy
3,991
+731
+22% +$64.4K 0.19% 101
2020
Q1 		$248K Sell
3,260
-1,623
-33% -$138K 0.18% 40
2019
Q4 		$432K Sell
4,883
-236
-5% -$19.6K 0.23% 68
2019
Q3 		$388K Buy
5,119
+192
+4% +$13.2K 0.2% 66
2019
Q2 		$323K Buy
4,927
+1,354
+38% +$106K 0.15% 70
2019
Q1 		$288K Buy
3,573
+32
+0.9% +$2.62K 0.1% 79
2018
Q4 		$326K Buy
+3,541
New +$311K 0.12% 42

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Fulcrum Equity Management's ABBV Position: Q2 2026 in Review

Fulcrum Equity Management reduced its AbbVie (ABBV) stake by 5.3% in Q2 2026, selling an estimated $15.5K and leaving 1,283 shares worth $323K. The position accounts for 0.24% of the portfolio, ranked #99.

Fulcrum Equity Management first reported a position in ABBV in Q4 2018 and has held it in 27 quarters since. The position peaked at $1.42M in Q3 2024. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Fulcrum Equity Management held 1,283 shares of AbbVie worth $323K as of Q2 2026.
  • Fulcrum Equity Management sold 72 AbbVie shares in Q2 2026, an estimated $15.5K.
  • AbbVie made up 0.24% of Fulcrum Equity Management's portfolio in Q2 2026, its #99 holding.
  • Fulcrum Equity Management first reported a position in AbbVie in Q4 2018 and has held it in 27 quarters since.
  • Fulcrum Equity Management's AbbVie position peaked at $1.42M in Q3 2024.
  • 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fulcrum Equity Management's 13F filing for Q2 2026, filed 9 Jul 2026.